Reata Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Reata Pharmaceuticals

10/05/2023 14:32

* Reata Pharmaceuticals Inc  RETA.OQ  reported a quarterly
adjusted loss of $3.14​​ per share for the quarter ended in
March. The mean expectation of ten analysts for the quarter was
for a loss of $2.42 per share.
    * Revenue fell 78.7% to $195.00 thousand from a year ago;
analysts
expected $158.25 thousand. 
    * Reata Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $3.14​.
    * The mean earnings estimate of analysts had fallen by
about 6% in
the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * Reata Pharmaceuticals Inc shares had risen by 15.9% this
quarter and gained 177.4% so far this year.
    * The company reported a quarterly loss of $116.12 million.
    * Wall Street's median 12-month price target for Reata
Pharmaceuticals Inc is $110.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
10 at 01:32 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -2.42          -3.14          Missed
 Dec. 31 2022      -2.21          -2.33          Missed
 Sep. 30 2022      -2.18          -2.16          Beat
 Jun. 30 2022      -2.02          -2.02          Met